QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Cytori Therapeutics, Inc. (CYTX) Announces Japanese Cell Therapy Study For Peripheral Artery Disease 0 comments
    Sep 14, 2012 10:56 PM | about stocks: CYTX

    Cytori Therapeutics is a company developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to cardiovascular disease and repair soft tissue defects. The company's therapies are made available through its proprietary device, the Cellution System, which automates the extraction and preparation of clinical grade ADRCs at the point-of-care.

    The company's scientific data suggests ADRCs improve blood flow, moderate the immune response, and keep tissue at risk of dying alive. Additionally, positive results have been reported from Europe with regards to the treatment of ischemic heart failure using ADRCs. Cytori therefore believes that these cells can be applied across multiple ischemic conditions.

    The company today announced that a 40-patient, multi-center investigator-sponsored and funded clinical study in Japan using the Cellution System has been approved under the Ministry of Health, Labor, and Welfare Guidelines on Clinical Research Using Human Stem Cells. The principal investigator in the study is Toyoaki Murohara, M.D., Ph.D., Professor and Chairman, Department of Cardiology at the primary trial center, Nagoya University Graduate School of Medicine. Two other Japanese sites will also participate in the study.

    The study will enroll patients with peripheral artery disease (PAD), Burger's disease, or with severe limb ischemia caused by connective tissue disease. PAD is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs. Each patient will receive an injection of their own ADRCs into the skeletal muscle at the affected area on the limb. Patients will undergo follow-up exams at one week and at one, three, and six months with primary endpoints being the safety of the treatment and limb salvage rates as compared to conventional treatment.

    For further information about Cytori Therapeutics and its Cellution System family of products, please visit the company's website at cytori.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CYTX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.